1
/
of
1
Custom Adenine Base Editor (Plasmid)
Custom Adenine Base Editor (Plasmid)
SKU:
Regular price
$595
Regular price
Sale price
$595
Unit price
/
per
Selected promoter is too long for this design
Couldn't load pickup availability
Precision A-to-G base editing in plasmid format for transient expression or screening. Choose from single-vector designs featuring compact ABE8e variants (SpCas9, SaCas9, CjCas9, Nme2Cas9, SauriCas9) with complementary PAM specificities. Ideal for target validation, dose-response optimization, cell engineering workflows, or any application requiring flexible, non-viral delivery.
Payload
U6-(gRNA)-(pro)-ABE7.10-bGHpA: Express gRNA under U6 and ABE7.10 under selected pro for original adenine base editing with broad literature validation. Uses the following parts:
- ABE7.10 Base Editor: First adenine base editor validated in human cells, achieving ~50% A-to-G conversion at positions 4–7 with ≤0.1% indels. Addresses the class of pathogenic mutations responsible for ~48% of disease-causing SNPs. Foundational reference for all subsequent ABE development, using an evolved TadA*–SpCas9 D10A nickase heterodimer.
- bGH PolyA Signal: Compact (225 bp) polyadenylation signal from bovine growth hormone with 3-fold higher expression than SV40 early polyA in key mammalian cell types. Size advantage over SV40 polyA makes it the preferred terminator for AAV vectors with limited cargo space. Standard terminator in commercial gene therapy and lentiviral vector platforms with decades of in vivo validation.
- U6 Promoter: RNA polymerase III promoter that drives constitutive expression of small RNAs. Provides strong, stable transcription with precise transcriptional start and termination sites.
U6-(gRNA)-(pro)-ABE8e-bGHpA: Expresses sgRNA under U6 and ABE8e under selected promoter for single-AAV adenine base editing with NNGRRT PAM. Uses the following parts:
- ABE8e Base Editor: Enhanced ABE with 590-fold faster deamination than ABE7.10. PACE evolution enables 1.5-3× improved efficiency with broader editing window.
- bGH PolyA Signal: Compact (225 bp) polyadenylation signal from bovine growth hormone with 3-fold higher expression than SV40 early polyA in key mammalian cell types. Size advantage over SV40 polyA makes it the preferred terminator for AAV vectors with limited cargo space. Standard terminator in commercial gene therapy and lentiviral vector platforms with decades of in vivo validation.
- U6 Promoter: RNA polymerase III promoter that drives constitutive expression of small RNAs. Provides strong, stable transcription with precise transcriptional start and termination sites.
U6-(gRNA)-(pro)-SaABE8e-bGHpA: Express sgRNA under U6 and SaABE8e under selected promoter for single-AAV adenine base editing with NNGRRT PAM. Uses the following parts:
- SaABE8e Base Editor: Compact adenine base editor using S. aureus Cas9 (NNGRRT PAM). TadA8e deaminase provides 590-fold faster deamination than ABE7.10 with editing window at positions 4-9.
- bGH PolyA Signal: Compact (225 bp) polyadenylation signal from bovine growth hormone with 3-fold higher expression than SV40 early polyA in key mammalian cell types. Size advantage over SV40 polyA makes it the preferred terminator for AAV vectors with limited cargo space. Standard terminator in commercial gene therapy and lentiviral vector platforms with decades of in vivo validation.
- U6 Promoter: RNA polymerase III promoter that drives constitutive expression of small RNAs. Provides strong, stable transcription with precise transcriptional start and termination sites.
U6-(gRNA)-(pro)-SaABE8e-V106W-bGHpA: Express sgRNA under U6 and SaABE8e V106W under selected promoter for minimized off-target RNA editing. Uses the following parts:
- SaABE8e-V106W Base Editor: SaABE8e variant with V106W mutation in TadA* domain, reducing off-target RNA editing while maintaining DNA editing efficiency.
- bGH PolyA Signal: Compact (225 bp) polyadenylation signal from bovine growth hormone with 3-fold higher expression than SV40 early polyA in key mammalian cell types. Size advantage over SV40 polyA makes it the preferred terminator for AAV vectors with limited cargo space. Standard terminator in commercial gene therapy and lentiviral vector platforms with decades of in vivo validation.
- U6 Promoter: RNA polymerase III promoter that drives constitutive expression of small RNAs. Provides strong, stable transcription with precise transcriptional start and termination sites.
U6-(gRNA)-(pro)-SaKKH-ABE8e-bGHpA: Express sgRNA under U6 and SaKKH-ABE8e under selected promoter for expanded NNNRRT PAM targeting scope. Uses the following parts:
- SaKKH-ABE8e Base Editor: Expanded-PAM variant of SaABE8e with KKH mutations (E782K/N968K/R1015H) enabling NNNRRT PAM recognition.
- bGH PolyA Signal: Compact (225 bp) polyadenylation signal from bovine growth hormone with 3-fold higher expression than SV40 early polyA in key mammalian cell types. Size advantage over SV40 polyA makes it the preferred terminator for AAV vectors with limited cargo space. Standard terminator in commercial gene therapy and lentiviral vector platforms with decades of in vivo validation.
- U6 Promoter: RNA polymerase III promoter that drives constitutive expression of small RNAs. Provides strong, stable transcription with precise transcriptional start and termination sites.
U6-(gRNA)-(pro)-CjABE8e-bGHpA: Expresses sgRNA under U6 and CjABE8e under selected promoter for ultra-compact single-AAV delivery. Uses the following parts:
- CjABE8e Base Editor: Ultra-compact adenine base editor using Campylobacter jejuni Cas9. Smallest ABE architecture (~3.8 kb) with 22-nt protospacer and editing window at positions 3-11.
- bGH PolyA Signal: Compact (225 bp) polyadenylation signal from bovine growth hormone with 3-fold higher expression than SV40 early polyA in key mammalian cell types. Size advantage over SV40 polyA makes it the preferred terminator for AAV vectors with limited cargo space. Standard terminator in commercial gene therapy and lentiviral vector platforms with decades of in vivo validation.
- U6 Promoter: RNA polymerase III promoter that drives constitutive expression of small RNAs. Provides strong, stable transcription with precise transcriptional start and termination sites.
U6-(gRNA)-(pro)-Nme2ABE8e-bGHpA: Express sgRNA under U6 and Nme2ABE8e under selected promoter for A/T-rich region targeting with N4CC PAM. Uses the following parts:
- Nme2ABE8e Base Editor: Ultra-compact adenine base editor using Nme2Cas9 with N4CC PAM, enabling targeting of A-rich sequences.
- bGH PolyA Signal: Compact (225 bp) polyadenylation signal from bovine growth hormone with 3-fold higher expression than SV40 early polyA in key mammalian cell types. Size advantage over SV40 polyA makes it the preferred terminator for AAV vectors with limited cargo space. Standard terminator in commercial gene therapy and lentiviral vector platforms with decades of in vivo validation.
- U6 Promoter: RNA polymerase III promoter that drives constitutive expression of small RNAs. Provides strong, stable transcription with precise transcriptional start and termination sites.
U6-(gRNA)-(pro)-SauriABE8e-bGHpA: Express sgRNA under U6 and SauriABE8e under selected promoter for alternative PAM specificity and genome coverage. Uses the following parts:
- SauriABE8e Base Editor: Compact adenine base editor using S. auricularis Cas9, providing alternative PAM specificity for expanded targeting.
- bGH PolyA Signal: Compact (225 bp) polyadenylation signal from bovine growth hormone with 3-fold higher expression than SV40 early polyA in key mammalian cell types. Size advantage over SV40 polyA makes it the preferred terminator for AAV vectors with limited cargo space. Standard terminator in commercial gene therapy and lentiviral vector platforms with decades of in vivo validation.
- U6 Promoter: RNA polymerase III promoter that drives constitutive expression of small RNAs. Provides strong, stable transcription with precise transcriptional start and termination sites.
Specifications
High-copy plasmid DNA produced in E. coli with pMB1 origin of replication and ampicillin resistance marker. Purified by endotoxin-reduced anion-exchange chromatography (PureLink Maxi) and resuspended in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). Purity confirmed by A260/A280 spectrophotometry (≥1.8). Identity confirmed by Sanger or long-read sequencing. Yield ≥500 µg. Store at −20°C. Avoid repeated freeze-thaw cycles.
Deliverables
- Plasmid DNA at ≥500 µg, endotoxin-reduced maxiprep
- Payload sequence file
- QC report (A260/A280 ratio, concentration, restriction digest or sequencing confirmation)
- Ships on dry ice
References
Share
